AIAnton A. Ishchenko

Anton A. Ishchenko

*This is an algorithmically generated author record based on publicly available information.

Anton A. Ishchenko has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surface-enhanced Raman spectroscopy in women with benign and malignant endometrial diseases

    by Vladimir M. Zuev, Dmitrii V. Lystsev, Dmitrii N. Artem’eV, Lyudmila A. Bratchenko, Vladimir I. Kukushkin, Tat’yAna A. Fedorova, Oksana A. Bystrykh, Anton A. Ishchenko, Aida V. Gilyadova, Лысцев Дмитрий Валерьевич

    Background. This study aimed to enhance early detection of endometrial cancer in women and distinguish benign conditions from endometrial cancer using surface-enhanced Raman scattering (SERS) analysis of blood plasma, thus increasing diagnostic efficacy. Materials and methods. The study of blood plasma from 95 female patients aged 22–79 years was performed. The patients were divided into four groups: group 1 included 29 women with endometrial adenocarcinoma, group 2 included 31 patients with endometrial polyp, group 3 included 10 women with endometrial hyperplasia, and the comparison group consisted of 25 healthy women. Blood plasma was analyzed via SERS, with three Raman spectra recorded per sample. Spectral measurements of the SERS substrate were assessed using dried samples on an experimental bench equipped with the spectrometric system RL785 (LLC “Foton-Bio”, Russia), incorporating a CCD detector, laser radiation source with a wavelength of 785 nm, and ADF U300 microscope (ADF, China). A silver substrate composed of dried silver colloid was used to demonstrate the enhancement effect on the Raman signal from the surface of the blood plasma. Results. Spectral and specific features that distinguish adenocarcinoma, polyps, and endometrial hyperplasia were identified and evaluated. Spectral and quantitative differences specific to each condition, which are crucial for the differential diagnosis of pathologic tissues, were also identified. The accuracy rates of the optical diagnostics in distinguishing endometrial adenocarcinoma from the control group and endometrial hyperplasia were 87% and 85%, respectively, for the calibration and verification spectral sets (where the sensitivity and specificity were 66% and 92% for the spectral verification set, respectively). The accuracy rates of distinguishing control from endometrial hyperplasia and endometrial adenocarcinoma were 86% and 85%, respectively, and the accuracy of distinguishing endometrial hyperplasia from control and endometrial adenocarcinoma was 81% for the calibration and verification sets of spectra. In addition, the study demonstrated improved accuracy in differentiating adenocarcinoma from hyperplasia, including polyps. The accuracy rate was 93% in the calibration set of spectra, with sensitivity and specificity of 96% and 90%, whereas in the validation set, it was 91%, with sensitivity and specificity of 93% and 88%, respectively. Conclusions. The study demonstrated the potential use of SERS for differentiating expression patterns in endometrial cancer from those in benign conditions.


  • Open Access

    Debate on the oncologic potential of sex steroid preparations

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    Background. Thanks to numerous worldwide studies, the significant contribution of the hormonal component to the oncological risks of the organs of the female reproductive system is beyond doubt. Of great interest is the analysis of world research on the oncological potential of hormonal drugs, namely COCs and MGT, since this issue continues to be one of the most complex and controversial. Aim. This study aimed to contribution of hormonal factors to the development of cancer of the female reproductive system, namely breast, cervical, endometrial and ovarian cancers. Materials and Methods. The study was conducted on the basis of the Center of Gynecology and Reproductive Technologies of the FSAU “National Medical Research Center “Treatment and Rehabilitation Center” of the Ministry of Health of the Russian Federation, the Department of Oncogynecology of the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University. The analysis of medical documentation for the period from January 2015 to December 2021 was carried out. The study included 1842 patients with verified oncological disease of the female reproductive system, who had a history of taking hormonal drugs of the following pharmacological groups: hormonal contraceptives, menopausal hormone therapy drugs. The age of all patients ranged from 26 to 83 years (mean age 51.98±10.3 years). The control group consisted of 611 patients without oncological diseases, who have a history of indications for taking hormonal drugs of these pharmacological groups. Results. When assessing the effect of the duration of MGT intake on the risk of developing breast cancer, it was found that MGT intake for a total of more than 6 years was associated with a higher risk of developing breast cancer (HR 1.18; CI 1.02–1.36; p 0.001). Using the Wald method, we found that the probability of developing breast cancer is associated with a BMI of more than 25 kg/m2 and long-term intake of combined MGT for a total of more than 6 years. When assessing the effect of the duration of MGT intake on the risk of developing RTM, it was found that MGT intake for a total of more than 6 years was associated with a higher risk of developing RTM (HR 1,432; CI 1,172–1,750; p 0.001). Using the Wald method, we found that the probability of developing RTM is associated with the presence of a BMI of more than 25 kg/m2, prolonged MGT intake for a total of more than 6 years and the presence of endometrial hyperplastic processes, adenomyosis, hypertension in the anamnesis. When assessing the effect of the duration of COC intake on the risk of developing breast cancer, it was found that taking COC for a total of more than 7 years was associated with a higher risk of developing breast cancer (HR 1.68; CI 1.1–2.5; p=0.010). According to the Wald method, it was revealed that the probability of developing breast cancer is associated with the presence of HPV type 16, a BMI of more than 25 kg/m2 and prolonged intake of COCs for a total of more than 7 years. When assessing the effect of the duration of MGT intake on the risk of developing PC, it was found that MGT intake for a total of more than 9 years was associated with a higher risk of developing PC (HR 1.65; CI 1.2–2.3; p=0.010). Using the Wald method, we found that the probability of developing RYA is associated with the presence of a BMI of more than 25 kg/m2, MGT intake and the presence of endometrial hyperplastic processes in the anamnesis. Conclusions. With prolonged use of sex steroids, there is a tendency to increase the risk of developing cancer of the female reproductive system. Careful follow-up and limitation of the duration of taking sex steroids in risk groups will reduce carcinogenic risks.

  • Long-term outcomes of surgical interventions for different types of pelvic organ prolapse

    by Anatolii I. Ishchenko, Ailar Asambaeva, Anton A. Ishchenko, Irina D. Khokhlova, Tea A. Dzhibladze, Elena G. Malyuta, Leonid S. Aleksandrov, Oksana Yu. Gorbenko, Ekaterina V. Tevlina, Mikhail B. Ageev, et al.

    Background. The study aimed to comparatively analyze the nature and frequency of complications and the severity of recurrences among patients with different forms of pelvic organ prolapse (POP). These factors will be examined depending on the surgical technique employed. Materials and methods. The study involved a thorough clinical evaluation, surgical intervention, and outpatient monitoring (at 1, 6, 12, 24, and 36 months) of 523 participants, aged 32–80 years, categorized into four main groups and 3–4 subgroups depending on the type of POP and surgical method used. Group 1 comprised 161 women (30.8%) presenting with grade I–III cervical elongation combined with grade I–II anterior vaginal wall prolapse. Group 2 consisted of 207 (39.6%) patients with grade II–III anterior vaginal wall prolapse, whereas group 3 included 107 patients (20.5%) with complete uterine prolapse. Group 4 was made up of 48 women (9.1%) with grade II–III posterior vaginal wall descent. Results. Based on the acquired data, synthetic implant extrusion commonly took place 6–12 months after the surgical procedure. Of the 158 patients who received polypropylene endoprostheses, 20 (12.7%) experienced extrusion and required repeated hospitalizations for partial or complete excision, followed by restoration of vaginal wall integrity. POP recurrences typically occurred 12–36 months after surgical treatment and were detected in 69 (13.2%) of 523 patients. The reappearance of symptoms of pelvic organ descent was most commonly identified in patients who underwent surgery using their tissues (26.6%), less frequently with synthetic implants (12.7%), and extremely rarely with titanium endoprostheses (1.6%). Conclusions. The results revealed that patients, who underwent surgery using original techniques, employing titanium-made mesh implants and anchors, experienced the fewest complications and postoperative POP incidence. Conversely, the use of synthetic implants increases the likelihood of mesh-associated complications and disease recurrence, necessitating partial or complete excision. The use of autologous tissue for POP surgery is related to a higher likelihood of recurring prolapse symptoms.


  • Open Access

    Cervical carcinogenesis associated with the use of combined oral contraceptives: is there a relationship?

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    BACKGROUND: Cervical cancer is one of the leading cancers in women of reproductive age. The etiological role of the human papillomavirus (HPV) in cancer development is long known and undisputed. However, owing to the widespread use of combined oral contraceptives (COCs), scientists actively investigate possible mechanisms of interrelation between sex steroids and HPV in terms of cervical cancer risk. AIM: This study aimed to assess the risk of cervical cancer in women of reproductive age, depending on the use of COCs for different durations. MATERIALS AND METHODS: The study included 411 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the Russian Ministry of Health and the Department of Oncogynecology at the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University between January 2015 and December 2021. All patients were divided into two groups. The study group included 291 patients with verified cervical cancer, and the control group included 120 patients without cancer. RESULTS: The study group was significantly more likely to take COCs (56, or 19.2%) than the control group (11, or 6.5%; p=0.018). In addition, the study group had significantly longer treatment durations (p=0.011). Overweight (n = 52, or 17.9%) and grade II obesity (n = 11, or 3.8%, vs. 0; p=0.03) were significantly more common in the study group than in the control group (n = 8, or 4.7%; p=0.003). The result of the multivariate analysis showed that taking COCs negatively affect cervical cancer development (p=0.018; odds ratio (OR) 1.230; CI 1.064–1.423). The receiver operating characteristic analysis revealed that the use of COCs has a high predictive value for determining the risk of cervical cancer (area under the curve, AUC=0.742); the sensitivity and specificity of this predictor were 74.07% and 72.73%, respectively. In the assessment on the effect of duration of COC use on the risk of cervical cancer, the results showed that total use of COCs for over 7 years was associated with a higher risk of cervical cancer development (p=0.010; OR 1.68; CI 1.1–2.5). CONCLUSIONS: Prescribing COCs in patients with HPV infection requires a personalized approach to consider etiologic factors of cervical cancer and reduce possible carcinogenic risks.


  • Open Access

    Phenomenon of hormone-dependent polyneoplasia of the female reproductive system

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    BACKGROUND: Primary multiplicity of malignant tumors of the female reproductive system is the least studied area of clinical oncology. In addition, the steady rise in the number of patients and various localizations of polyneoplasia with lesions of the female reproductive organs necessitate a detailed study of this problem. AIM: This study aimed to determine the incidence and risk factors and describe the clinical aspects of polyneoplasia of the female reproductive system for 20102021 in women seen at the Medical and Rehabilitation Center of the Ministry of Health of Russia, Moscow, and the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University. MATERIALS AND METHODS: We conducted a retrospective analysis of the case records of 147 patients with a confirmed diagnosis of polyneoplasia of the female reproductive system for 20102021, which accounted for 3.6% of all newly diagnosed neoplasms of the female reproductive system in the above medical institutions. Moreover, a continuous sampling method was used. RESULTS: Breast cancer was the most frequent first tumor, combined with cancer of the contralateral breast in 27 (42.1%) patients, cancer of the uterine body in 4 (6.25%) patients, ovarian cancer in 4 (6.25%) patients, colon cancer in 4 (6.25%) patients, and thyroid cancer in 1 (1.5%) patient. Cancer of the uterine body was combined with breast cancer in 10 (35.7%) patients, ovarian cancer in 2 (7.1%) patients, thyroid cancer in 2 (7.1%) patients, and colon cancer in 3 (11.1%) patients. Endometrioid adenocarcinoma, pathogenic variant I was determined in 20 (71.4%) cases according to the histological structure. Thyroid cancer was detected in 7 (5.6%) cases; in all cases, it developed metachronously, and it was combined as the initial tumor with breast cancer in 1 (14.3%) case, uterine body cancer in 2 (28.5%) cases, and ovarian cancer in 1 (14.3%) case. As the second tumor, it was also combined with uterine body cancer in 2 (28.5%) cases and ovarian cancer in 1 (14.3%) case. The risk factors assessment led to the identification of several factors that are common in patients with hormone-dependent forms of primary multiple cancer, including obesity, diabetes mellitus, irregular menstrual cycle, history of proliferative diseases of the mammary glands, intake of thyroid drugs, uterine hyperplastic processes, and hypothyroidism. CONCLUSIONS: Understanding the different aspects of the development and course of hormone-dependent polyneoplasia of the female reproductive system will help in developing approaches for follow-up monitoring of women who have been treated for a primary tumor and are at risk of developing a subsequent tumor of hormone-dependent organs, to prevent the recurrence of the disease and predict the subsequent tumor and ensure its timely detection.

  • Open Access

    Assisted reproductive technology and uterine cancer risk. A systematic review and meta-analysis

    by Lidia A. Klyukina, Elena A. Sosnova, Anton А. Ishchenko, Клюкина Лидия Александровна

    BACKGROUND: The problem of infertility has not only medical, but also socio-demographic significance. To date, the global scale of the spread of various forms of infertility is beyond doubt among specialists around the world. This, in turn, causes an increase in the frequency of prescribing assisted reproductive technologies, but the question of the relationship between the prescribing of drugs used to treat infertility and the risk of developing cancer of the uterine body remains poorly understood. AIM: The aim of this study was to assess the possible relationship between in vitro fertilization, the use of ovulation stimulation drugs and the risk of developing uterine cancer in women with infertility. MATERIALS AND METHODS: This literature systematic review is based on resources from the following databases: Medline, ClinicalKey, Google Scholar, Embase, the Cochrane Library, and eLIBRARY for the period 19992022. The search for publications was carried out using keywords defined in accordance with the PICO principle (P, population or patients; I, intervention; C, comparison; O, outcomes): female, women, infertility, infertility treatment, in vitro fertilization, IVF, assisted reproductive technology, ART, ovarian stimulation, ovarian hyperstimulation, clomiphene citrate, hCG, hMG, tamoxifen, uterine, endometrial, cancer, carcinoma neoplasm, uterine neoplasm. The following SQL operators were used during the search: AND and OR. RESULTS: The search resulted in 37 representative publications, with eight studies selected for meta-analysis. CONCLUSIONS: This systematic review and meta-analysis have demonstrated the ambiguity of the design and results of studies on the possible relationship of uterine cancer and assisted reproductive technology methods published to date. The issue under review is urgent due to the high frequency of infertility and an increase in the frequency of gynecologic cancers. The conducted studies confirm that it is impossible to evaluate the carcinogenic effect of ovulation inducers or in vitro fertilization methods without adjusting for the infertility factor, as well as risk factors for uterine cancer. There is still a high need for further research, particularly for studying the safety profile of infertility treatment methods in relation to long-term cancer risks.

  • Carcinogenic Potential Of Ovulation Stimulation In BRCA1/2 Gene Mutation Carriers In Assisted Reproductive Technology Programs

    by Lidia A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko

    Mutations of the BRCA1/2 genes constitute a fundamental and independent risk factor in the genesis of both breast cancer and ovarian cancer. The specifics of the infertility treatment effect on the risk of developing cancer in carriers of mutations in the BRCA1/2 genes remain unclear and require a comprehensive investigation. In this review, we analyzed published sources on the possible relationship between the infertility treatment and the risk of ovarian and breast cancer in BRCA1/2 mutation carriers.


  • Vaginal extirpation of the uterus using implants made of titanium silk to prevent recurrence of the disease

    by Anatoliy I. Ishchenko, Tat'YAna V. Gavrilova, Anton A. Ishchenko, Oksana Y. Gorbenko, Teya A. Dzhibladze, Irina D. Khokhlova, Leonid S. Aleksandrov

    INTRODUCTION: The frequency of post-hysterectomy prolapse of the vaginal dome reaches 43% in patients after surgical treatment for complete uterine prolapse. Goal ― improving the effectiveness of surgical treatment with titanium mesh implants in pre- and postmenopausal patients with complete uterine prolapse. MATERIALS AND METHODS: The study involved 21 patients with complete uterine prolapse who underwent the proposed new method of transvaginal surgical prevention of post-hysterectomy prolapse of the vaginal dome. The result of surgical treatment was evaluated by analyzing the data of vaginal examination and ultrasound. RESULTS: Patients were observed for 2 years ― after 1, 6, 12 and 24 months. Analysis of vaginal examination and ultrasound data showed no displacement of the vaginal dome, pelvic organs and deformation of titanium implants. There were no mesh-associated complications during follow-up. CONCLUSIONS: The use of the developed surgical method for the correction of post-hysterectomy prolapse of the vaginal dome with the use of implants made of titanium silk is a reliable tool that provides anatomical efficiency in pre- and postmenopausal patients.

  • Contraceptive history and risk of cancer of the female reproductive organs: the realities of today (literature review)

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Клюкина Лидия Александровна

    In modern conditions, an increasing number of women resort to the use of hormonal contraception drugs, and their number is constantly increasing, but systematic studies on the possible role of hormonal contraceptives as independent triggers or cofactors of the development of oncological diseases of the reproductive system are currently few, which does not allow us to draw objective conclusions. In this paper, we analyzed global data on the risks and frequency of detected oncopathology of the reproductive organs, taking into account the contraceptive history of women.